Our Antimicrobial Arsenal
At Arcum Therapeutics, our portfolio reflects a strategic vision: to identify, invest in, and accelerate breakthrough innovations that combat microbial threats and protect global health.
We focus on science-driven companies with transformative potential—technologies that truly work. All of the assets in our portfolio demonstrate significant efficacy and redefine how we treat infectious diseases in the face of growing antimicrobial resistance (AMR).
Our Approach
We leverage our strategic relationship with the University of Rochester to commercialize some of the most promising and cutting-edge anti-infective technologies.
We pursue products with broad-spectrum potency and unique mechanisms of action to create a more robust defense from antimicrobial resistance.
Our companies develop therapeutics against the most critical resistant pathogens including the ESKAPE pathogens and WHO Bacterial Priority Pathogens List (BPPL).
Portfolio Companies
Honeoye Remedies
Honeoye Remedies is redefining everyday skincare and cosmetics. Its flagship skin balm harnesses the healing power of medical-grade Manuka honey to soothe, protect, and support the skin’s natural recovery—without synthetic antibiotics. Gentle, effective, and antibiotic-free, it’s the modern replacement for Neosporin in every home first-aid kit.
TI-Arcum
TI-Arcum is a joint venture between Arcum Therapeutics and the leading Dermatology CRO- Therapeutics Incorporated. TI-Arcum is developing therapies for skin and soft tissue infections (SSTIs) through synergistic antibiotic combinations. Designed for broad-spectrum coverage and reduced resistance development, our innovative formulation offers a powerful new option for treating serious SSTIs in both hospital and outpatient settings.
Assets in Discovery
Novel Compounds
Discovered from natural products located across the world in unexpected places confirming the 25 year old Luedemann Hypothesis
Antifungal Therapies
By applying our synergistic combination discovery techniques to anti fungal therapies we have discovered several potent antifungal agents
Novel Combination Products
We continue to search for new synergistic drug combinations and reformulate known combinations for critical areas of clinical need
